ObjectiveTo investigate the clinical effect of montelukast sodium in patients with asthmatic COPD overlap syndrome and its effect on lung function. MethodsA total of 100 patients with asthmatic COPD overlap syndrome diagnosed and treated in our hospital from March 2016 to March 2019 were selected, and were divided into two groups by the random number table method. Fifty patients in control group were administered conventional treatment, based on which another 50 patients in research group were additionally administered montelukast sodium. The efficacy was compared between the two groups; the forced expiratory volume in the first second (FEV1), forced vital capacity (FVC), forced expiratory volume in the first second to forced vital capacity ratio (FEV1/FVC), inspiratory fraction ［deep inspiratory capacity (IC)/total lung capacity (TLC)］ of patients before treatment and 1 month after treatment were compared between both groups. ResultsAfter 1 month of treatment, the clinical efficacy of the research group was significantly superior to that of the control group. The total effective rate (96.0%) was significantly higher than that of the control group (84.0%), and the differences were statistically significant (P＜0.05). FEV1, FVC, FEV1/FVC, and IC/TLC of patients in both groups significantly increased, and the levels of patients in the research group were significantly higher than those in the control group, with the statistically significant differences (P＜0.05). ConclusionOn the basis of conventional treatment, additionally employing montelukast on asthmatic COPD overlap syndrome has a prominently clinical effect, which can significantly improve the lung function, and promote a speedy recovery of patients.

无